Sanibel Captiva Trust Company Inc. Sells 2,549 Shares of DexCom, Inc. (NASDAQ:DXCM)

Sanibel Captiva Trust Company Inc. trimmed its stake in DexCom, Inc. (NASDAQ:DXCM) by 18.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,580 shares of the medical device company’s stock after selling 2,549 shares during the quarter. Sanibel Captiva Trust Company Inc.’s holdings in DexCom were worth $1,313,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. SeaCrest Wealth Management LLC lifted its holdings in DexCom by 3.6% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock worth $501,000 after purchasing an additional 152 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in DexCom during the 2nd quarter worth approximately $2,909,000. China Universal Asset Management Co. Ltd. lifted its holdings in DexCom by 33.2% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 2,614 shares of the medical device company’s stock worth $296,000 after purchasing an additional 652 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in DexCom by 46.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,467 shares of the medical device company’s stock worth $166,000 after purchasing an additional 465 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its holdings in DexCom by 6.0% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 615,131 shares of the medical device company’s stock worth $69,744,000 after purchasing an additional 34,905 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total value of $49,126.35. Following the sale, the executive vice president now owns 75,877 shares in the company, valued at approximately $8,729,648.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $49,126.35. Following the completion of the transaction, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at $8,729,648.85. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,135 shares of company stock worth $446,797. Insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on DXCM shares. Canaccord Genuity Group reissued a “buy” rating and set a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. JPMorgan Chase & Co. cut DexCom from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $145.00 to $75.00 in a report on Friday, July 26th. Royal Bank of Canada dropped their price objective on DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a report on Friday, July 26th. Morgan Stanley dropped their price objective on DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a report on Friday, July 26th. Finally, Oppenheimer dropped their price objective on DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $111.63.

DexCom Price Performance

Shares of DXCM traded down $4.84 during midday trading on Tuesday, hitting $72.85. The company’s stock had a trading volume of 7,571,847 shares, compared to its average volume of 3,780,220. The stock has a market capitalization of $28.97 billion, a price-to-earnings ratio of 47.61, a price-to-earnings-growth ratio of 2.18 and a beta of 1.16. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The company’s fifty day simple moving average is $98.89 and its two-hundred day simple moving average is $117.69.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. DexCom’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.34 EPS. As a group, equities analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.